RA Capital Management - Q1 2014 holdings

$1.39 Billion is the total value of RA Capital Management's 35 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 45.2% .

 Value Shares↓ Weighting
GILD NewGILEAD SCIENCES INCput$170,064,0002,400,000
+100.0%
12.20%
ACAD  ACADIA PHARMACEUTICALS INCcall$127,733,000
-2.6%
5,250,0000.0%9.16%
-40.1%
SGMO BuySANGAMO BIOSCIENCES INCcall$108,480,000
+160.3%
6,000,000
+100.0%
7.78%
+60.3%
SGMO SellSANGAMO BIOSCIENCES INC$94,415,000
+30.0%
5,222,053
-0.1%
6.77%
-19.9%
ACHN  ACHILLION PHARMACEUTICALS IN$76,874,000
-0.9%
23,366,0070.0%5.51%
-39.0%
DRNA NewDICERNA PHARMACEUTICALS INC$68,607,0002,428,571
+100.0%
4.92%
DYAX BuyDYAX CORP$66,780,000
+447.2%
7,436,470
+359.1%
4.79%
+236.8%
TXMD SellTHERAPEUTICSMD INC$62,081,000
+2.2%
9,838,449
-15.6%
4.45%
-37.1%
OPHT BuyOPHTHOTECH CORP$61,998,000
+19.7%
1,737,856
+8.6%
4.45%
-26.3%
ENTA NewENANTA PHARMACEUTICALS INC$61,628,0001,541,078
+100.0%
4.42%
PRTA SellPROTHENA CORP PLC$59,569,000
+36.9%
1,554,918
-5.3%
4.27%
-15.7%
ARWR BuyARROWHEAD RESH CORP$48,306,000
+117.3%
2,941,916
+43.6%
3.46%
+33.7%
BCRX  BIOCRYST PHARMACEUTICALS$45,996,000
+39.2%
4,347,4560.0%3.30%
-14.3%
NVAX SellNOVAVAX INC$45,020,000
-18.7%
9,938,250
-8.1%
3.23%
-49.9%
DVAX  DYNAVAX TECHNOLOGIES CORP$32,331,000
-7.8%
17,883,9540.0%2.32%
-43.2%
SNSS  SUNESIS PHARMACEUTICALS INC$32,186,000
+39.5%
4,869,2610.0%2.31%
-14.2%
XNCR  XENCOR INC$31,964,000
+28.3%
2,725,0000.0%2.29%
-21.0%
PTCT BuyPTC THERAPEUTICS INC$25,663,000
+101.0%
981,761
+30.5%
1.84%
+23.7%
RPRX NewREPROS THERAPEUTICS INC$25,529,0001,439,048
+100.0%
1.83%
TSRO  TESARO INC$20,636,000
+4.4%
700,0000.0%1.48%
-35.7%
NBIX NewNEUROCRINE BIOSCIENCES INC$18,822,0001,169,084
+100.0%
1.35%
DSCI SellDERMA SCIENCES INC$16,979,000
-21.3%
1,339,039
-32.9%
1.22%
-51.6%
MRTX  MIRATI THERAPEUTICS INC$12,525,000
+14.7%
656,7670.0%0.90%
-29.4%
BLUE  BLUEBIRD BIO INC$10,629,000
+8.4%
467,4180.0%0.76%
-33.3%
PSDV BuyPSIVIDA CORP$10,478,000
+122.2%
2,555,659
+115.2%
0.75%
+36.8%
ITMN NewINTERMUNE INC$10,068,000300,801
+100.0%
0.72%
ACHN  ACHILLION PHARMACEUTICALS INcall$9,870,000
-0.9%
3,000,0000.0%0.71%
-39.0%
FLXN NewFLEXION THERAPEUTICS INC$7,403,000450,000
+100.0%
0.53%
ACAD SellACADIA PHARMACEUTICALS INC$6,083,000
-79.2%
250,000
-78.6%
0.44%
-87.2%
OCRX SellOCERA THERAPEUTICS INC$5,568,000
-35.2%
527,797
-20.2%
0.40%
-60.1%
MGNX  MACROGENICS INC$5,549,000
+1.5%
199,3980.0%0.40%
-37.5%
ALIM NewALIMERA SCIENCES INC$5,260,000666,667
+100.0%
0.38%
MEIP  MEI PHARMA INC$4,545,000
+38.9%
408,3330.0%0.33%
-14.4%
DYAX  DYAX CORPcall$4,490,000
+19.2%
500,0000.0%0.32%
-26.7%
PRAN NewPRANA BIOTECHNOLOGY LTDcall$280,000100,000
+100.0%
0.02%
CNDO ExitCORONADO BIOSCIENCES INCcall$0-1,000,000
-100.0%
-0.31%
CHTP ExitCHELSEA THERAPEUTICS INTL LT$0-666,667
-100.0%
-0.34%
ENZ ExitENZO BIOCHEM INC$0-2,268,653
-100.0%
-0.77%
RMTI ExitROCKWELL MED INCput$0-1,000,000
-100.0%
-1.22%
NLNK ExitNEWLINK GENETICS CORPcall$0-500,000
-100.0%
-1.28%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-05-15
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q1 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%
ARYA Sciences Acquisition Corp VSold outMay 15, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-25
42024-04-15
42024-04-15
SC 13G2024-04-15
SC 13D/A2024-04-12
SC 13G2024-04-12
SC 13D/A2024-04-11
SC 13G2024-04-11
42024-04-04
SC 13G2024-04-04

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings